FK-506 VERSUS CYCLOSPORINE IN THE PREVENTION OF RENAL-ALLOGRAFT REJECTION EUROPEAN PILOT-STUDY - 6-WEEK RESULTS

被引：45
作者：
SCHLEIBNER, S [1 ]
KRAUSS, M [1 ]
WAGNER, K [1 ]
ERHARD, J [1 ]
CHRISTIAANS, M [1 ]
VANHOOFF, J [1 ]
BUIST, L [1 ]
MAYER, D [1 ]
机构：
[1] QUEEN ELIZABETH HOSP,LIVER & KIDNEY TRANSPLANT UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND
来源：
TRANSPLANT INTERNATIONAL | 1995年 / 8卷 / 02期
关键词：
FK; 506; CYCLOSPORINE; KIDNEY TRANSPLANTATION;
D O I：
10.1007/BF00344416
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
FK 506 was compared with cyclosporin in a randomised trial in good-risk cadaveric renal transplant recipients. The objective was to evaluate whether oral FK 506 dosing was viable and whether blood concentrations in the range 10-20 ng/ml would prove to be practical. Thirty-one adult patients were randomised to FK 506 and 16 to cyclosporin. Both groups received an identical regimen of azathioprine and corticosteroids. Serum creatinine concentrations decreased rapidly in both groups with mean values below 200 mu mol/l within 2 weeks. One graft in the cyclosporin group was lost due to renal vein thrombosis. During the 6-week study period, 19.4 % of patients on FK 506 and 31.3 % on cyclosporin experienced acute rejection. One patient in each group experienced corticosteroid-resistant rejection that responded to anti-lymphocyte therapy. Infections were reported in 51.6 % of the FK 506 group compared with 37.5 % of the cyclosporin group. The spectrum of adverse events was similar in both groups. However, minor neurological disorders were more common in the FK 506 group (54.8 % versus 6.3 %) whereas hypertension was less common (48.8 % versus 75.0 %). The results indicate that oral FK 506 rapidly achieves therapeutic blood concentrations and is an effective immunosuppressant for the initial treatment of renal allograft recipients.
引用
收藏
页码：86 / 90
页数：5
相关论文
共 9 条
  • [1] Cecka J.M., Early rejection: determining the fate of renal transplants, Transplant Proc, 23, pp. 1263-1264, (1991)
  • [2] Fung J., Todo S., Abu-Elmagd K., Jain A., Tzakis A., Martin M., Selby R., Bronsther O., Doyle H., Gayowski T., Ramos H., Kishida A., Starzl T., Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine, Transplant Proc, 25, (1993)
  • [3] Grenier F.C., Luczkiw J., Bergmann M., Lunetta S., Morrison M., Blonski D., Shoemaker K., Kobayashi M., A whole blood FK 506 assay for the IMx analyser, Transplant Proc, 23, pp. 2748-2749, (1991)
  • [4] Japanese study of FK 506 on kidney transplantation: results of an early phase II study, Transplant Proc, 23, pp. 3071-3074, (1993)
  • [5] Japanese study of FK 506 on kidney transplantation: results of late phase II study, Transplant Proc, 25, pp. 649-654, (1993)
  • [6] Krentz A.J., Dousset B., Mayer A.D., McMaster P., Buckels J., Cramb R., Smith J.M., Nattrass M., Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients, Diabetes, 42, pp. 1753-1759, (1993)
  • [7] Shapiro R., Jordan M., Scantlebury V., Fung J., Jensen C., Tzakis A., McCauley J., Carroll P., Ricordi C., Demetris A.J., Mitchell S., Jain A., Iwaki Y., Kobayashi M., Reyes J., Todo S., Hakala T.R., Simmons R.L., Starzl T.E., FK 506 in clinical transplantation, Transplant Proc, 23, pp. 3065-3067, (1991)
  • [8] Shapiro R., Jordan M.L., Scantlebury V.P., Fung J.J., Jensen C., Vivas C., McCauley J., Irish W.D., Mitchell S., Demetris A.J., Randhawa P., Jain A., Tzakis A., Hakala T.R., Simmons R.L., Starzl T.E., Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report, Transplant Proc, 25, pp. 669-672, (1993)
  • [9] Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation, Tansplant Proc, 25, pp. 679-688, (1993)
1